Company Filing History:
Years Active: 2011
Title: Paolo Avalle: Innovator in Tyrosine Kinase Inhibitors
Introduction
Paolo Avalle is a notable inventor based in Hertford, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of tyrosine kinase inhibitors. His work is crucial in the fight against various cellular proliferative diseases, including cancer.
Latest Patents
Paolo Avalle holds a patent for a compound that serves as a tyrosine kinase inhibitor. The patent, titled "Tyrosine kinase inhibitors," relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N'-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]sulfamide. This invention is particularly focused on the sodium salt of the compound, which is effective against the receptor tyrosine kinase MET. The applications of this invention are vast, targeting diseases such as cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders, and inflammation.
Career Highlights
Paolo Avalle is currently associated with Merck & Co., Inc., where he continues to innovate in the pharmaceutical sector. His work has led to advancements in treatments that can significantly improve patient outcomes in various medical conditions.
Collaborations
Paolo collaborates with esteemed colleagues, including Jennifer R Foley and Peter Mullens. Their combined expertise enhances the research and development efforts within their field.
Conclusion
Paolo Avalle's contributions to the development of tyrosine kinase inhibitors represent a significant advancement in medical science. His innovative work continues to pave the way for new treatments that can address critical health challenges.